Abstract
66 Early Experiences of the Use of Combination Immunotherapy for the Treatment of Malignant Mesothelioma from 2022–2023 – Real-World Evidence of 1-Year Data from a Single UK Tertiary Cancer Centre
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
